Norepinephrine Infusion Combined With Goal-directed Fluid Therapy Reduces Delayed Graft Function Incidence in Patients Undergoing Kidney Transplantations: a Randomized Multicenter Clinical Trial

Status: Recruiting
Location: See all (3) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

Delayed graft function (DGF), delineated by the necessity for dialytic intervention within the initial week post-transplantation, afflicts approximately 20%-50% of recipients. The primary objective of this study is to investigate the potential efficacy of norepinephrine infusion in conjunction with goal-directed fluid therapy (GDFT) in mitigating the occurrence of DGF among individuals undergoing kidney transplantations. The findings of this investigation have the potential to advance the field of perioperative care in kidney transplantations by providing insights into optimized management strategies.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Recipients aged 18 years or older

• Scheduled to undergo kidney transplantations under general anesthesia

• Cadaveric kidney transplantations

• Sign the informed consent form

Locations
Other Locations
China
Renji Hospital
RECRUITING
Shanghai
General Hospital of Northern Theatre Command
NOT_YET_RECRUITING
Shenyang
the First Affiliated Hospital of Zhengzhou University
NOT_YET_RECRUITING
Zhengzhou
Contact Information
Primary
Diansan Su, Dr.
diansansu@yahoo.com
+862168383702
Backup
Muyan Shi, B.S.
jsqdsmy@163.com
+862168383702
Time Frame
Start Date: 2024-03-01
Estimated Completion Date: 2026-06-30
Participants
Target number of participants: 380
Treatments
Experimental: Goal-Directed Fluid Therapy (GDFT) group
Following anesthesia induction, patients will be connected to the FlowTrac/Vigileo monitoring system to facilitate the recording of pertinent hemodynamic parameters, including stroke volume variation (SVV), stroke volume, and cardiac output. Then, Norepinephrine Infusion Combined with Goal-directed Fluid Therapy will be administered. Efforts are made to sustain a mean arterial pressure (MAP) of ≥ 80 mmHg.
Active_comparator: Regular Fluid Therapy group
Patients will not undergo monitoring with the FlowTrac/Vigileo system throughout the whole procedure. Anesthesiologists will rely on their clinical expertise and intraoperative circulatory hemodynamic assessment to regulate fluid infusion rates and administer medications as necessary to sustain a mean arterial pressure (MAP) of ≥ 80 mmHg until the conclusion of the surgical procedure.
Sponsors
Leads: RenJi Hospital

This content was sourced from clinicaltrials.gov

Similar Clinical Trials